Vimpat
lacosamide
Table of contents
Overview
Vimpat is a medicine used on its own or as an add-on to other epilepsy medicines in the treatment of partial-onset seizures (epileptic fits starting in one specific part of the brain) with or without secondary generalisation (where the abnormal electrical activity spreads through the brain) in patients with epilepsy aged 4 years and older
Vimpat can also be used as add-on to other epilepsy medicines in the treatment of primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 4 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
Vimpat contains the active substance lacosamide.
-
List item
Vimpat : EPAR - Medicine overview (PDF/125.32 KB)
First published: 17/09/2008
Last updated: 29/01/2021
EMA/649412/2020 -
-
List item
Vimpat : EPAR - Risk-management-plan summary (PDF/201.94 KB)
First published: 05/09/2019
Last updated: 29/01/2021
Authorisation details
Product details | |
---|---|
Name |
Vimpat
|
Agency product number |
EMEA/H/C/000863
|
Active substance |
lacosamide
|
International non-proprietary name (INN) or common name |
lacosamide
|
Therapeutic area (MeSH) |
Epilepsy
|
Anatomical therapeutic chemical (ATC) code |
N03AX18
|
Publication details | |
---|---|
Marketing-authorisation holder |
UCB Pharma SA
|
Revision |
34
|
Date of issue of marketing authorisation valid throughout the European Union |
29/08/2008
|
Contact address |
Product information
01/12/2020 Vimpat - EMEA/H/C/000863 - WS/1782
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Antiepileptics
Therapeutic indication
Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.